安旭生物12月23日获融资买入196.84万元，融资余额9599.36万元

Group 1 - The core viewpoint of the news is that Anxu Bio's stock performance and financial metrics indicate a challenging period, with significant declines in revenue and net profit year-over-year [2] - On December 23, Anxu Bio's stock price remained unchanged at 0.00%, with a trading volume of 10.05 million yuan, and a net financing purchase of 241,600 yuan [1] - As of December 23, the total balance of margin trading for Anxu Bio was 95.99 million yuan, which is 1.95% of its market capitalization, indicating a low financing balance compared to the past year [1] Group 2 - For the period from January to September 2025, Anxu Bio reported a revenue of 325 million yuan, a year-over-year decrease of 19.34%, and a net profit of 64.36 million yuan, down 52.60% compared to the previous year [2] - The number of shareholders for Anxu Bio increased by 1.10% to 6,090 as of September 30, while the average number of circulating shares per person decreased by 1.08% to 20,867 shares [2] - Anxu Bio has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2]